Regenxbio (RGNX) Total Non-Current Liabilities (2018 - 2025)

Regenxbio's Total Non-Current Liabilities history runs 8 years deep, the most recent figure standing at $349.7 million for Q4 2025.

• On a quarterly basis, Total Non-Current Liabilities rose 72.5% year-over-year to $349.7 million in Q4 2025; TTM through Dec 2025 was $349.7 million, a 72.5% increase from a year earlier, with the FY2025 full-year figure at $349.7 million, up 72.5% from the prior year.
• Total Non-Current Liabilities fell to $349.7 million in Q4 2025 per RGNX's latest filing, from $363.1 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $366.7 million in Q2 2025 and bottomed at $178.1 million in Q2 2021.
• The 5-year median for Total Non-Current Liabilities is $249.8 million (2023), against an average of $258.1 million.
• Across the five-year window, Total Non-Current Liabilities jumped 652.67% in 2021 and sank 30.95% in 2024, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $178.3 million in 2021, then gained by 0.68% to $179.5 million in 2022, then increased by 21.88% to $218.7 million in 2023, then retreated by 7.33% to $202.7 million in 2024, then surged by 72.5% to $349.7 million in 2025.
• Per Business Quant, the three latest RGNX Total Non-Current Liabilities figures stand at $349.7 million (Q4 2025), $363.1 million (Q3 2025), and $366.7 million (Q2 2025).